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Introduction: Osteocalcin (OC) is used as a surrogate marker for bone turnover in clinical 40 
settings. As bone mineral density (BMD) is largely heritable, we tested the hypothesis that a) 41 
bone-associated genetic variants previously identified in Genome-Wide Association Studies 42 
(GWAS) and combined into a genetic risk score (GRS) are associated with a) circulating levels 43 
of OC and b) the changes in OC following acute exercise.   44 
Methods: Total OC (tOC), undercarboxylated OC (ucOC), and carboxylated OC (cOC) were 45 
measured in serum of 73 healthy Caucasian males at baseline and after a single bout of high-46 
intensity interval exercise. In addition, genotyping was conducted targeting GWAS variants 47 
previously reported to be associated with BMD and then combined into a GRS. Potential 48 
associations between the GRS and tOC, ucOC and cOC were tested with linear regressions 49 
adjusted for age.  50 
Results: At baseline none of the individual SNPs associated with tOC, ucOC and cOC. 51 
However, when combined, a higher GRS was associated with higher tOC (β = 0.193ng/mL; 52 
p=0.037; 95% CI = 0.012, 0.361) and cOC (β = 0.188ng/mL; p=0.04; 95% CI = 0.004, 0.433). 53 
Following exercise, GRS was associated with ucOC levels, (β = 3.864ng/mL; p-value = 0.008; 54 
95% CI = 1.063, 6.664) but not with tOC or cOC.   55 
Conclusion: Screening for genetic variations may assist in identifying people at risk for 56 
abnormal circulating levels of OC at baseline/rest. Genetic variations in BMD predicted the 57 
ucOC response to acute exercise indicating that physiological functional response to exercise 58 
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 63 
Introduction 64 
The primary function of the skeletal system is to provide mechanical support of the body, 65 
respond to outside mechanical forces, and is a reservoir for normal mineral metabolism [1, 2]. 66 
Throughout the lifespan the skeleton undergoes continuous bone remodelling, it is tightly 67 
controlled by osteoclasts and osteoblasts which balance bone removal and bone formation [3]. 68 
In-vivo bone remodelling is difficult to assess, therefore circulating bone turnover markers 69 
(BTMs) are commonly used in a clinical setting as a surrogate  measure for bone metabolism 70 
and give an indication of bone turnover [4, 5].  71 
Osteocalcin (OC), a BTM, is secreted by osteoblasts into the extracellular matrix and is 72 
important in bone matrix formation, mineralization and maintenance [6, 7]. OC can be post-73 
translationally modified by gamma (ƴ)-carboxylation at one or more of the three (17, 21 and 74 
24) glutamic acid residues and found in two different forms, carboxylated (cOC) and 75 
undercarboxylated OC (ucOC). While they share a similar tertiary structure they are thought 76 
to have different biological functions. The undercarboxylated form (ucOC) was implicated in 77 
energy metabolism and cardiovascular health [4, 8-10]. UcOC may also play a role in bone 78 
health as higher levels of ucOC have been found to be associated with a higher risk of hip 79 
fracture [11-13]. While cOC, where all three glutamic acid residues are carboxylated, is 80 
considered predominantly a protein of the bone matrix [6, 9]. After carboxylation 81 
conformational changes occur in OC, increasing the affinity for calcium ions [9]. Calcium helps 82 
to stabilize OC and facilitates the binding of OC to the surface of hydroxyapatite, the bone 83 
mineral component of the bone and is closely aligned with the bone mineral density (BMD) [4, 84 
6].  85 
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BMD is a parameter used in the identification of people at risk for osteopenia and osteoporosis 86 
[14, 15]. BMD has a high genetic heritability with contributions from environmental factors 87 
such as exercise and nutrition [16-18]. A recent Genome-Wide Association (GWAS) study 88 
identified nine single nucleotide polymorphisms (SNPs) that are associated with BMD (p< 5 89 
X 10-6) [16]. Environmental factors such as acute exercise can also affect BTMs by 90 
mechanically loading the skeleton [19-21]. We have also previously shown that the ACTN3 91 
R577X common SNP is associated with serum levels of tOC in men with serum levels higher 92 
in the ACTN3 XX genotype (α-actinin-3 deficiency) compared to RR and RX at baseline [22]. 93 
This illustrates both genetic and environmental factors can influence bone turnover and the 94 
associated markers [23, 24]. Any imbalances to this process can cause bone loss and a reduction 95 
in bone strength leading to common bone disorders such as osteopenia and osteoporosis [25].  96 
However, it is currently unclear whether bone related genetic variants are associated with levels 97 
of bone turnover, nor if genetic variants can alter the response of BTMs following acute 98 
exercise. This could be clinically important in identifying people at a younger age at risk of 99 
bone related disorders. Therefore, we tested the hypothesis that the GWAS SNPs that were 100 
previously identified to be associated with bone-related phenotypes [16], can predict 101 
circulating tOC, ucOC and cOC at baseline, and following an acute bout of High-Intensity 102 
Interval Exercise (HIIE).   103 
Materials and methods 104 
Participants 105 
This study is a part of the Genes and Skeletal Muscle Adaptive Response to Training (Gene 106 
SMART) study. The detailed methodology has previously been published [26]. Briefly, 107 
seventy-three apparently healthy, Caucasian men (age = 31.4 years ± 8.2; BMI = 25.2 kg/m2 ± 108 
3.2) participated in the study following a written informed consent. Participants attended the 109 
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VU laboratory on 2 separate occasions, to perform two graded exercise tests, and on one 110 
occasion for the blood sampling and the acute exercise intervention. Volunteers were excluded 111 
if they had a bone disease, were taking hypoglycaemic medications, warfarin or vitamin K 112 
supplementation, or medications that affect bone metabolism, insulin secretion, or sensitivity. 113 
Further, participants with known musculoskeletal or other conditions that prevent daily activity 114 
were excluded from the study. This study was approved by the Human Ethics Research 115 
Committee at Victoria University (HRE13-223) and all participants provided written informed 116 
consent. 117 
Aerobic Capacity (Graded exercise test) 118 
Aerobic capacity was assessed by a graded exercise test (GXT) to establish peak power output 119 
(Wpeak) and lactate threshold (LT). Briefly the test consisted of 4 minute exercise stages, 120 
separated by 30 second rest periods until voluntary exhaustion. Capillary blood samples were 121 
collected and analysed by the YSI 2300 STAT Plus system (Ohio, USA) at the end of each 4 122 
minute stage and immediately after exhaustion to establish lactate (LT) concentration. LT was 123 
calculated by the modified DMAX method as previously described [26].   124 
Nutrition consultation 125 
Each participant was provided with an individualised pre-packaged diet 48 hours prior to 126 
providing the blood samples to standardise diet across the participants and minimise the effects 127 
of this confounding factor [27, 28]. The content of the diets were based on the current 128 
Australian National Health and Medical Research Council (NHMRC) guidelines. Participants 129 
were asked to abstain from food, caffeine and alcohol 12 hours prior to blood collection. 130 
Acute exercise session 131 
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Participants completed a single session of High Intensity Interval Exercise (HIIE) on a cycle 132 
ergometer (Velotron®, Racer Mate Inc.). The acute exercise session consisted of 8 X 2min 133 
intervals at 40% of [(Wpeak-LT) + LT] with 1 minute active recovery intervals at a power of 134 
60W.   135 
 Serum osteocalcin measurements 136 
Before acute exercise (baseline), immediately after the acute exercise, and 3 hours post 137 
exercise, venous blood samples were collected via venepuncture or cannulation in BD SST 138 
Vacutainers (Becton and Dickson Company, USA). All participants abstained from food, 139 
caffeine and alcohol 12 hours prior to blood collection in the morning to control for variation 140 
in serum levels of OC. They were left at room temperature (10 mins) before being centrifuged 141 
at 3500 rpm for 10mins at 4°C. Serum was collected and stored at -80°C. tOC was measured 142 
using an automated immunoassay (Elecys 170; Roche Diagnostics). This assay has a sensitivity 143 
of 0.5 µg.L-1 with an intra-assay precision of 1.3%. We measured  ucOC by the same immuno-144 
assay after absorption of carboxylated OC on 5mg/ml hydroxyl-apatite slurry as described by 145 
Gundberg et al. [29]. cOC was calculated by the subtracting the ucOC from the tOC. 146 
Circulating tOC, ucOC and cOC were measured at baseline (before acute exercise), 147 
immediately after, and 3 hours post exercise. The peak OC, ucOC and cOC was considered the 148 
maximal concentration immediately after or 3 hours post exercise 149 
Genotyping 150 
Genomic DNA was extracted from residual blood samples from BD Vacutainer EDTA tubes 151 
using the MagSep Blood gDNA kit (0030 451.00, Eppendorf, Hamburg, Germany) [26]. The 152 
genotype of each SNP was assessed by the Australian Genome Research Facility (AGRF). We 153 
chose the SNPs based on previous literature from a GWAS study assessing BMD [16]. The 154 
SNPs, locus, type, effect allele and closest gene are described in supplementary table 1. Based 155 
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on the Moayyeri et al GWAS, nine genetic variants known to be associated with broadband 156 
ultrasound attenuation (BUA), that estimates BMD, were used to calculate genetic risk scores 157 
(GRS).The SNPs were measured by MassARRAY® combined with iPLEX® chemistry 158 
(Agena Bioscience).    159 
 Statistical analysis 160 
We conducted linear regressions to test for potential associations between individual SNPs and 161 
tOC or cOC levels, using an additive genetic model (i.e. homozygotes for non-effect allele 162 
coded as 0; heterozygotes coded as 1; homozygotes for effect allele coded as 2). The GRS was 163 
calculated by coding each SNP with the number of effect alleles (0, 1 or 2), multiplying this 164 
with the published regression coefficient (beta) [16] then summed up to obtain a weighted GRS. 165 
Linear regressions were conducted to test whether the GRS was associated with tOC, ucOC or 166 
cOC. The distribution of tOC, ucOC and cOC were checked for normality visually using 167 
histograms, and tOC, ucOC and cOC were log-transformed to meet normality assumptions. In 168 
the linear regressions, we used log-transformed tOC, ucOC or cOC as the dependent variable; 169 
and GRS and age as the independent variables. We also tested BMI, and fitness parameters 170 
(VO2peak, lactate threshold and peak power) as additional covariates, but as they did not 171 
significantly associate with levels of tOC, ucOC or cOC they were removed from the model. 172 
To investigate the response of tOC, ucOC and cOC to exercise and potential associations with 173 
the GRS, we used the delta change of baseline to peak before and after the acute exercise 174 
session. Where required p-values from the statistical analyses were adjusted for multiple testing 175 
using the false discovery rate (FDR) [30], and q-values<0.05 were deemed significant. Post-176 
hoc power analysis was conducted in R using the pwr package using effect sizes and notations 177 





Participants’ characteristics and the tOC, ucOC and cOC responses to exercise are described 181 
in Table 1. A small, but significant (4.6%, p<0.05) increase was observed for tOC, and ucOC 182 
(10.1%, p<0.01) but not cOC, following exercise (Table 1).  183 
Table 1- Participant characteristics (n=73) 184 
 Baseline 
 
Age (years) 31.4 ± 8.2 
BMI (kg.m-2) 25.2 ± 3.2 
VO2peak (mL.kg-1.min-1) 47.2 ± 8.0 
Lactate threshold (W) 206.7 ± 55.3 
Wpeak (W) 294.9 ± 64.7 
Circulating Osteocalcin  Peak p-value 
tOC (ng/ml) 30.5 ± 10.9 31.9 ± 10.65 p=0.004 
cOC (ng/ml) 18.7 ± 8.2 19.1 ± 7.8 p=0.372 
ucOC (ng/ml) 11.9 ± 4.3 13.1 ± 4.6 P<0.01 
BMI, Body Mass Index; VO2peak, Peak oxygen uptake during graded exercise test; Peak, peak 185 
level of tOC, ucOC and cOC at either immediately post or 3 hours post exercise; tOC, total 186 
osteocalcin; cOC, Carboxylated OC; ucOC, under-carboxylated osteocalcin; W, watts. Values 187 
are mean ± SD. 188 
Individual SNPs were not associated with tOC, ucOC and cOC 189 
We first assessed the contribution of each individual SNP to the variance in tOC, ucOC and 190 
cOC, but no significant associations were found (Table 2). 191 
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Table 2- Individual SNP regression analysis with tOC, ucOC and cOC. 192 
  tOC cOC ucOC 



























rs7741021 0.08 0.82 0.92 5.3 0.144 0.71 0.71 5.6 0.124 0.889 0.889 0.05 
rs4869739 -0.19 0.54 0.69 7.9 -0.218 0.57 0.64 7.5 -0.385 0.655 0.75 0.066 
rs3020331 0.29 0.38 0.68 11.6 0.348 0.39 0.64 11.6 0.449 0.616 0.75 0.072 
rs2982552 0.80 0.02 0.19 55 0.82 0.059 0.3 39.3 1.75 0.07 0.63 0.075 
rs2908007 0.22 0.13 0.39 27 0.232 0.18 0.54 21.3 0.309 0.423 0.75 0.054 
rs597319 0.01 0.98 0.98 0.5 0.217 0.57 0.64 7.6 -0.873 0.299 0.672 0 
rs10416265 -0.25 0.49 0.69 8.8 -0.32 0.47 0.64 9.1 -0.429 0.667 0.75 0.14 
rs6974574 0.62 0.21 0.47 19.1 0.544 0.37 0.64 11.6 1.588 0.243 0.67 0.17 
rs38664 0.90 0.06 0.28 37.8 1.091 0.068 0.31 37 1.672 0.212 0.67 0.9 
The p-values were adjusted for multiple testing using the false discovery rate (FDR). Additive genetic models were used. Effect size correspond 193 




The GRS was positively associated with tOC, ucOC and cOC 196 
As the contribution of each individual SNP may be too small to be detected in only n = 73 197 
individuals, we calculated a GRS to increase statistical power (see Material & Methods). Age 198 
was negatively associated with tOC (β = -0.608ng/ul; p<0.001; 95% CI = -0.017, -0.009), ucOC 199 
(β = -0.018ng/ml; p<0.001; 95% CI= -0.027, -0.009) and cOC (β = -0.607ng/ml; p<0.001; 95% 200 
CI = -0.017, -0.009). After adjusting for age, higher GRS was associated with higher levels of 201 
tOC (β = 0.193ng/ml; p-value = 0.037; 95% CI = 0.012, 0.361) and with higher levels of cOC 202 
(β = 0.188ng/ml p-value = 0.046; 95% CI = 0.004, 0.433). The GRS explained 6.1% of the 203 
variance in tOC and 5.6% of the variance in cOC (Figure 1). ucOC was not associated with 204 















Figure 1- Regression analysis of genetic risk score with tOC,ucOC and cOC adjusted for 218 
age. BMD GRS = Bone Mineral Density Genetic Risk Score. Significance p<0.05 after 219 




The GRS was associated with exercise-induced peak in ucOC but not tOC or cOC 222 
A positive association was identified between ucOC response to exercise and the GRS (β = 223 
3.864ng/ml; p-value = 0.008; 95% CI = 1.063, 6.664). The GRS explained 9.8% of the variance 224 
in ucOC response to exercise (Figure 2). We were unable to identify an association between 225 
the changes in tOC or cOC and the GRS (p=0.617 and p=0.17, respectively).  226 
 227 
Figure 2- Regression analysis of genetic risk score with change in ucOC (Δ) after acute 228 
exercise. BMD GRS = Bone Mineral Density Genetic Risk Score. Significance p<0.05 after 229 
adjusting for age. 230 
 231 
Discussion 232 
We report that a higher GRS is associated with higher tOC and cOC at baseline in healthy 233 
young men but not with ucOC. GRS did not appear to predict the change in tOC or cOC 234 
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following exercise. However, a higher genetic risk for lower BMD was associated with the 235 
increased concentration of ucOC following exercise, providing a novel insight that BMD 236 
genetic variants may play a role in this response.  237 
BMD is a complex trait that, in part, relates to heritability and is used as a predictor for future 238 
risk to develop osteoporosis. Yet, each individual SNP may only contribute a small amount to 239 
the hereditary component of BMD, making this type of analysis not useful in predictive studies 240 
[32]. This is shown in table 2 where each individual SNP did not predict change in tOC, ucOC 241 
or cOC. GRS combines SNPs identified by GWAS into a score that can evaluate and provide 242 
further insights into the genetic contribution to BMD by increasing statistical power to detect 243 
these small contributions [32-34]. We used nine SNPs that were associated with BMD from an 244 
unbiased GWAS approach in large consortium [16] and found that these SNPs are also 245 
associated with the BTM, OC. The genetic variants used in the GRS determined 6.1% and 5.6% 246 
of the variability of circulating levels of tOC and cOC, respectively, at rest and 9.8% of the 247 
variability of circulating levels of ucOC in response to acute exercise. 248 
We report that healthy men who have a higher genetic risk for lower BMD displayed increased 249 
circulating levels of tOC. Previous studies have shown that higher levels of serum BTMs, 250 
including tOC are associated with higher bone turnover [22, 35, 36]. While OC is 251 
conventionally used as a marker of bone formation, literature suggests that it may be a better 252 
indicator of overall bone turnover [37, 38]. Studies have shown that osteoporosis, vertebral 253 
fractures, and bone loss are associated with increased levels of tOC [39, 40]. Therefore, we 254 
provide evidence indicating that genetics may be playing a role in influencing bone turnover, 255 
previously shown to be associated with ongoing bone loss or higher risk of fracture [37, 39, 256 
40].  257 
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Exercise mechanically loads the skeleton, improves insulin sensitivity and may partly mediate 258 
the interaction between muscle, bone and glucose metabolism [9, 20]. Therefore, we explored 259 
the hypothesis that BMD gene variants may play a role in tOC, ucOC or cOC response to acute 260 
exercise. We found that the genetic risk score was not associated  with tOC or cOC in response 261 
to acute exercise, suggesting that the genetic variables examined cannot determine the response 262 
of tOC or cOC to acute exercise, at least in healthy-young men [22]. We could speculate that 263 
as bone formation is a slow process [41], to observe any influence of BMD gene variants on 264 
circulating levels of tOC or cOC would require a longer exercise intervention. Interestingly, an 265 
increased genetics risk for a lower BMD was associated with increased levels of ucOC in 266 
response to exercise. It is not clear why those with increased genetic risks exhibited increased 267 
levels of ucOC following exercise, however, previous studies suggest that increased ucOC 268 
levels are associated with increased fracture risk [11-13]. In addition, the increase in ucOC 269 
following exercise may be due to the increase metabolic demands by skeletal muscle. Indeed, 270 
we have previously shown that ucOC has a direct effect on muscle glucose uptake in insulin 271 
signalling proteins [9, 42]. We confirmed that ucOC is upregulated after exercise in humans 272 
and provide a novel insight that BMD genetic variants may play a role in this response.  273 
The current study has some potential limitations. First, it includes a relatively small sample 274 
size in the context of genetic studies. Yet, even with a small sample size we were able to detect 275 
a significant association of GRS with tOC and cOC. We are confident in our findings, as they 276 
support previous findings of a GWAS that identified these SNPs to be associated with BMD 277 
[16]. We were underpowered for the individuals SNP analysis (on average tOC- 19.2%, ucOC- 278 
0.2% and cOC- 16.7%). However, our power improved greatly with the use of the genetic risk 279 
score (tOC- 48%, ucOC- 14.9% and cOC- 44%) illustrating the strength of calculating a GRS 280 
for data analysis. We acknowledge that while greater sample sizes are required, our data 281 
provides hypothesis generating pilot data that offer interesting novel concepts for future 282 
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analysis. Secondly, we did not assess BMD, therefore a direct assessment of the SNPs with 283 
BMD cannot be performed. Finally, we only tested young-healthy males. Future studies should 284 
focus on young healthy females as well as older adults who have an increased risk for 285 
osteopenia and osteoporosis.   286 
In conclusion, screening for genetic variations may assist in identifying people at risk for 287 
abnormal circulating levels of OC. Genetic variations in BMD predicted the response of ucOC 288 
to acute exercise, but not tOC or cOC, indicating that physiological functional response to 289 
exercise may be influenced by bone-related gene variants. 290 
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